Cardinal Capital Management Has $383,000 Stock Holdings in Haleon plc (NYSE:HLN)

Cardinal Capital Management increased its holdings in shares of Haleon plc (NYSE:HLN) by 12.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,091 shares of the company’s stock after acquiring an additional 4,866 shares during the period. Cardinal Capital Management’s holdings in Haleon were worth $383,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP lifted its holdings in shares of Haleon by 164.6% during the fourth quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after acquiring an additional 8,423,475 shares during the period. Cambiar Investors LLC acquired a new stake in shares of Haleon during the 4th quarter worth about $15,225,000. Goldman Sachs Group Inc. lifted its holdings in Haleon by 19.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 4,813,997 shares of the company’s stock valued at $39,619,000 after purchasing an additional 772,829 shares during the last quarter. Optiver Holding B.V. boosted its position in Haleon by 223.0% in the fourth quarter. Optiver Holding B.V. now owns 1,008,565 shares of the company’s stock valued at $8,260,000 after buying an additional 696,327 shares in the last quarter. Finally, Clearbridge Investments LLC boosted its position in Haleon by 2.4% in the fourth quarter. Clearbridge Investments LLC now owns 26,581,902 shares of the company’s stock valued at $218,769,000 after buying an additional 612,400 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Haleon Stock Performance

HLN stock opened at $8.43 on Friday. The company has a 50 day moving average price of $8.41 and a 200 day moving average price of $8.34. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $8.96. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73. The stock has a market capitalization of $38.49 billion, a PE ratio of 28.10, a price-to-earnings-growth ratio of 2.26 and a beta of 0.26.

Haleon (NYSE:HLN) last released its earnings results on Wednesday, May 1st. The company reported $0.12 EPS for the quarter, beating the consensus estimate of $0.11 by $0.01. Haleon had a return on equity of 13.17% and a net margin of 9.68%. The company had revenue of $3.70 billion during the quarter, compared to analysts’ expectations of $3.71 billion. Analysts forecast that Haleon plc will post 0.46 EPS for the current year.

Analysts Set New Price Targets

HLN has been the subject of several recent analyst reports. Berenberg Bank began coverage on shares of Haleon in a report on Wednesday, June 5th. They set a “buy” rating for the company. HSBC began coverage on Haleon in a research report on Wednesday, April 17th. They issued a “buy” rating for the company. Finally, Argus restated a “buy” rating on shares of Haleon in a report on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.